Uncategorised - European Medical Journal

IL-5 in Type 2 Inflammatory Diseases

Type 2 inflammation is involved in severe asthma (SA), chronic rhinosinusitis with nasal polyps (CRSwNP), and eosinophilic granulomatosis…

Unexpected Findings in Endometriosis

Endometriosis is defined as the presence of endometrial glands and stroma outside the uterine cavity, which commonly presents with…

Assessing CBNAAT for Extrapulmonary Tuberculosis Diagnosis: A Retrospective Study

Tuberculosis (TB) represents a significant global public health issue, ranking as the 13th leading cause of mortality and standing as the…

Diagnosing Radiographic Axial Spondyloarthritis: Challenges in a Young Adult Case from Guayaquil

Radiographic axial spondyloarthritis (r-axSpA), formerly known as ankylosing spondylitis (AS), is a chronic inflammatory disease that…

Knowledge, Attitude, and Preventive Practices on HPV Vaccination among Mothers of Adolescent Girls

Human papillomavirus (HPV) is a sexually transmitted infection linked to genital, anal, and oral warts, as well as cervical and other…

Adverse Drug Events from First-Line Anti-tuberculosis Drugs

Tuberculosis (TB) is caused by the bacteria Mycobacterium tuberculosis, a complex, rod-shaped, non-spore-forming, thin, aerobic bacterium…

Incidental Idiopathic Left Uncal Herniation

The uncus is a hook-shaped structure located on the most anteromedial aspect of the parahippocampal gyrus, which is part of the medial…

COPD Inhaler Safety: New Data Emerges

A recent study examining real-world COPD treatment outcomes has highlighted safety concerns regarding single-inhaler triple therapy compared to the long-acting beta2-agonist (LABA) and inhaled corticosteroid (ICS) combination, particularly in terms of cardiovascular risks.

Medical Histories That Defy Alzheimer’s

New research offers insights into medical factors linked to the absence of Alzheimer’s disease neuropathologic changes (ADNC) in individuals aged 90 and older.

PARP Inhibitor Shows Sustained Cancer Benefits: SABCS 2024

Patients with high-risk, BRCA-positive breast cancer receiving the PARP inhibitor olaparib after standard treatment continue to experience significant survival benefits, according to 6-year follow-up results from the Phase III OlympiA trial.